Inframe insertions of three or more base pairs in exon 20 of the epidermal growth factor receptor (gene were among the firstmutations to be identified as oncogenic drivers in non-small cell lung cancer (NSCLC). However, unlike the classicalL858R point mutation or exon 19 deletions, which ...
[1] Kwon CS, Lin HM, Crossland V, et al. Non-small cell lung cancer with EGFR exon 20 insertion mutation: a systematic literature review and meta-analysis of patient outcomes. Curr Med Res Opin. 2022 Aug;38(8)...
1.Francois Gonzalvez, Sylvie Vincent, et.al, Mobocertinib (TAK-788): A Targeted Inhibitor of EGFR Exon 20 Insertion Mutants in Non–Small Cell Lung Cancer, Cancer Discov (2021) 11 (7): 1672–1687. 2.Mengzhao Wa...
3.Yasuda H, Ichihara E, Sakakibara-Konishi J, et al. A phase I/II study of osimertinib in EGFR exon 20 insertion mutation-positive non-small cell lung cancer. Lung Cancer. 2021;162:140-146. doi:10.1016/j.lungcan.2021.10.006. 4.Girard N. WCLC 2020. Abstract MA04.07. 5.Yang G, Li...
4.Abstract CT102: Interim results of a first-in-human, dose escalation and expansion study of PLB-1004, an irreversible inhibitor of exon 20 insertion mutations in patients with non-small cell lung 5.TAS6417/CLN-081 is a pan-mutation-selective EGFR tyrosine kinase inhibitor with a broad spec...
[5]Kwon CS, Lin HM, Crossland V, et al. Non-small cell lung cancer with EGFR exon 20 insertion mutation: a systematic literature review and meta-analysis of patient outcomes. Curr Med Res Opin, 2022, 38(8): 1341-1350. doi: 10.1080/03007995.2022.2083326. ...
Table 1 Histologic and clinical characteristics of non-small cell lung cancer patients tested in this study Full size table Table 2 Clinical comparison of EGFR ex20ins NSCLC with EGFR Full size table Fig. 2 Distribution of EGFR mutations and EGFR exon 20 mutation types and EGFRex20ins in this...
[1] Kwon CS, Lin HM, Crossland V, et al. Non-small cell lung cancer with EGFR exon 20 insertion mutation: a systematic literature review and meta-analysis of patient outcomes. Curr Med Res Opin. 2022 Aug;38(8):1341-1350. [2] Pan B, Liang J, Shi H, et al. Epidemiological charact...
https://www.jnj.com/janssen-submits-application-to-u-s-fda-seeking-approval-of-amivantamab-for-the-treatment-of-patients-with-metastatic-non-small-cell-lung-cancer-with-egfr-exon-20-insertion-mutations. ...
Poziotinib produced an encouraging overall response rate in patients with non–small cell lung cancer harboring EGFR exon 20 mutations, meeting the primary end point in cohort 1 of a phase 2 trial.